Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels

Liver International

Volumn 31, Issue 9, 2011, Pages 1352-1358

  Cheong, Jae Y ^a   Kim, Dong J ^b   Hwang, Seong G ^c   Yang, Jin M ^d   Kim, Young B ^a   Park, Young N ^e   Cho, Sung W ^a  

^a Ajou University School of Medicine   (South Korea)

^b Hallym University College of Medicine   (South Korea)

^c CHA University   (South Korea)

^d The Catholic University of Korea College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

Apolipoprotein A1; AST; Chronic hepatitis; Serum marker; Significant inflammation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 18; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HYALURONIC ACID; PROCOLLAGEN TYPE 3; UNCLASSIFIED DRUG;

ACCURACY; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINO TERMINAL SEQUENCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CORRELATION ANALYSIS; FEMALE; FIBROSIS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; APOLIPOPROTEIN A-I; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; CHI-SQUARE DISTRIBUTION; CLINICAL ENZYME TESTS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INFLAMMATION MEDIATORS; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; NECROSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UP-REGULATION; YOUNG ADULT;

EID: 80052538813     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02570.x     Document Type: Article

References (30)

1. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
2. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39: 222-30.
3. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
4. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.
5. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
6. Rosenberg W M, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-13.
7. EASL. International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003; 38: 533-40.
8. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003; 38(Suppl. 1): S90-103.
9. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
10. EASL. Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
11. Lok AS, Mcmahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
12. Park JY, Park YN, Kim DY, et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat 2008 [Epub ahead of print].
13. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123: 330-7.
14. Conry-Cantilena C, Vanraden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-6.
15. Piton A, Poynard T, Imbert-Bismut F, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 1998; 27: 1213-9.
16. Linder S, Havelka AM, Ueno T, Shoshan MC. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 2004; 214: 1-9.
17. Grassi A, Susca M, Ferri S, et al. Detection of the M30 neoepitope as a new tool to quantify liver apoptosis: timing and patterns of positivity on frozen and paraffin-embedded sections. Am J Clin Pathol 2004; 121: 211-9.
18. Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 2001; 80: 230-9.
19. Bantel H, Lugering A, Poremba C, et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001; 34(Part 1): 758-67.
20. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
21. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-17.
22. Mohamadnejad M, Montazeri G, Fazlollahi A, et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 2006; 101: 2537-45.
23. Poynard T, Mchutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003; 38: 481-92.
24. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-7.
25. Chen EQ, Huang FJ, He LL, et al. Histological changes in Chinese chronic hepatitis B patients with ALT lower than two times upper limits of normal. Dig Dis Sci 2010; 55: 432-7.
26. Ter Borg F, Ten Kate FJ, Cuypers HT, et al. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis B e antigen. Lancet 1998; 351: 1914-8.
27. Geiss HC, Ritter MM, Richter WO, Schwandt P, Zachoval R. Low lipoprotein (a) levels during acute viral hepatitis. Hepatology 1996; 24: 1334-7.
28. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970-80.
29. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64: 1751-6.
30. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut 2008; 57: 500-6.